Attached files
file | filename |
---|---|
EX-10.1 - BIO BRIDGE SCIENCE INC | v205642_ex10-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
WASHINGTON,
D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT
TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
Date of
report (Date of earliest event reported): December 11,
2010
BIO-BRIDGE
SCIENCE, INC.
(Exact
name of registrant as specified in its charter)
000-51497
(Commission
File Number)
DELAWARE
|
20-1802936
|
(State
or other jurisdiction of incorporation or organization)
|
(IRS
Employer Identification No.)
|
1801
South Meyers Road, Suite 220, Oakbrook Terrace, IL, 60181
(Address
of Principal Executive Offices, Zip Code)
630-613-9687
(Registrant’s
telephone number,
including area code)
N/A
(Former
Name or Former Address, if Changed Since Last Report)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act
(17 CFR 240.13e-4(c))
Item
2.01. Completion of Acquisition or Disposition of
Assets.
On
December 11, 2010, Bio-Bridge Science (HK) Co. Ltd. (“BBS HK”), a wholly owned
subsidiary of Bio-Bridge Science, Inc. (“we”, “our”), entered into an Equity
Interest Transfer Contract (“the Contract”) with China Vaccine Corporation
Limited (“China Vaccine”), a Hong Kong company, whereby BBS HK agreed to sell to
China Vaccine all of the equity interest we held at our 51% owned subsidiary,
Bio-Bridge Xinheng Baide Biotechnology Co. Ltd. (“Bio-Bridge XB”), a company of
the People’s Republic of China.
China
Diamond, the company controlled by one of our directors, Trevor Roy, also
agreed, as a party to the Contract, to sell all of the equity interest (14%) it
held at Bio-Bridge XB to China Vaccine.
The sale
price of the combined equity interest (65%) is USD $342,772, or RMB 2.3 Million.
We will receive USD $268,944 pro rata.
As agreed
in the Contract, for the combined equity interest (65%), China Vaccine will pay
an earnest money of USD $50,000 within five days after the execution of the
Contract, and a second installment of USD $146,386 within six months, and the
final installment of USD $146,386 within twelve months, provided certain
conditions are met. We will receive the proceeds pro rata.
A copy of
the Contract is filed as Exhibit 10.1 to this Form 8-K.
Item
9.01. Financial Statements and Exhibits.
Exhibit No.
|
Description
|
|
10.1
|
Equity
Interest Transfer Contract
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, as amended, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Date:
December 15, 2010
/s/ Dr.
Liang Qiao
|
By:
Dr. Liang Qiao
|
Chief
Executive Officer
|
(Principal
Executive Officer)
|